Monlutenca (Lutetium (177lu) Chloride)

Lutetium-177 chloride emits beta particles that travel a short distance, causing DNA damage in cells that bind the radiolabelled ligand. After intravenous infusion, the compound binds to specific receptors on tumour cells, is internalised, and the emitted radiation destroys the cancer cells while largely sparing surrounding healthy tissue.

The dose of Monlutenca is determined individually by the prescribing physician based on the patient’s clinical condition, tumour burden, and prior therapies. Dosing regimens are tailored to each case and are not publicly standardized; the prescriber will calculate the appropriate activity for each treatment cycle.

Monlutenca is contraindicated in pregnant patients because the radiation can harm the developing fetus. Limited data exist for breastfeeding, and the drug may be excreted in milk; therefore, breastfeeding is generally not recommended during and for a period after treatment.

To request Monlutenca, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and assistance with import documentation.

Monlutenca belongs to the class of targeted radionuclide therapies similar to Lutathera (Lutetium‑177‑dotatate) for neuroendocrine tumours and Pluvicto (Lutetium‑177‑PSMA‑617) for prostate cancer. While the core radionuclide is the same, differences lie in the targeting ligand, which determines the specific tumour type and biodistribution. Clinical efficacy and safety profiles are comparable, with choice guided by tumour receptor expression.

Monlutenca must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and to comply with radiation safety regulations.

Monlutenca is administered as an intravenous infusion under the supervision of qualified healthcare professionals. The infusion is typically given in a controlled clinical setting, with monitoring of vital signs and blood parameters before, during, and after the procedure.

The most serious risks include severe myelosuppression leading to infection or bleeding, renal toxicity that can impair kidney function, hepatic toxicity, and the rare possibility of secondary malignancies due to radiation exposure. Patients should be closely monitored for blood count changes and organ function throughout therapy.

Monlutenca should not be used in pregnant women, individuals with severe renal impairment, uncontrolled infections, or those who have had a severe allergic reaction to Lutetium‑177 compounds. Patients with inadequate bone marrow reserve or who are receiving incompatible high‑dose chemotherapy should also be evaluated carefully before treatment.